IMCR · NASDAQ
Immunocore Holdings (IMCR) Stock Price & Fundamentals
Immunocore Holdings (IMCR) closed at $440.67 on Oct 9, 2026, down 1.13% from the previous close of $445.71.
Share price, past year
1Y +11.64%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $440.67 |
| Sep 30, 2026 | $454.60 |
| Aug 31, 2026 | $445.40 |
| Jul 31, 2026 | $431.91 |
| Jun 30, 2026 | $437.12 |
| May 29, 2026 | $430.54 |
| Apr 30, 2026 | $442.64 |
| Mar 31, 2026 | $423.94 |
| Feb 27, 2026 | $409.14 |
| Jan 30, 2026 | $392.74 |
| Dec 31, 2025 | $404.16 |
| Nov 28, 2025 | $382.31 |
| Oct 31, 2025 | $389.78 |
Key statistics
- Market cap
- $22.69B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.38
- Revenue (TTM)
- $430.78M
- Net income (TTM)
- −$18.07M
- Shares outstanding
- 51.5M
- Dividend yield
- —
- 52-week range
- $374.13 – $459.52
Immunocore Holdings's market cap is $22.69B, based on a share price of $440.67 and 51.5M shares outstanding as of Jun 30, 2026.
Financials
Immunocore Holdings reported revenue of $400.02M for fiscal 2025, up 28.95% from fiscal 2024.
Immunocore Holdings reported a net loss of $35.51M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 5 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $400.02M | +29.0% | −$35.51M | −8.9% | −$0.71 | −$15.05M |
| FY2024ended Dec 31, 2024 | $310.20M | +24.4% | −$51.09M | −16.5% | −$1.02 | $20.89M |
| FY2023ended Dec 31, 2023 | $249.43M | +43.1% | −$55.29M | −22.2% | −$1.13 | −$2.49M |
| FY2022ended Dec 31, 2022 | $174.36M | +377.9% | −$52.54M | −30.1% | −$1.15 | −$51.41M |
| FY2021ended Dec 31, 2021 | $36.48M | — | −$180.03M | −493.5% | −$4.24 | −$144.49M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $115.93M | −$808.00K | −$0.02 |
| Q1 FY2026ended Mar 31, 2026 | $106.68M | $12.97M | $0.25 |
| Q4 FY2025ended Dec 31, 2025 | $104.48M | −$30.06M | −$0.61 |
| Q3 FY2025ended Sep 30, 2025 | $103.69M | −$177.00K | $0.00 |
| Q2 FY2025ended Jun 30, 2025 | $97.96M | −$10.30M | −$0.20 |
| Q1 FY2025ended Mar 31, 2025 | $93.88M | $5.02M | $0.10 |
| Q4 FY2024ended Dec 31, 2024 | $84.05M | −$23.77M | −$0.47 |
| Q3 FY2024ended Sep 30, 2024 | $80.25M | $8.74M | $0.17 |
Company profile
- Name
- Immunocore Holdings plc
- Ticker
- IMCR
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 90 Park Drive, Milton Park, Abingdon, Oxfordshire, X0 OX14 4RY
- Incorporated in
- X0
- Fiscal year ends
- December
- SEC CIK
- 0001671927
Recent SEC filings
- Sep 14, 2026
- Aug 6, 2026
- Aug 6, 2026
- May 27, 2026
- May 6, 2026
- May 6, 2026
- Feb 25, 2026
- Feb 25, 2026
Frequently asked questions
What is Immunocore Holdings's stock price?
Immunocore Holdings (IMCR) closed at $440.67 on Oct 9, 2026, down 1.13% from the previous close of $445.71.
What is Immunocore Holdings's market cap?
Immunocore Holdings's market cap is $22.69B, based on a share price of $440.67 and 51.5M shares outstanding as of Jun 30, 2026.
How much revenue does Immunocore Holdings make?
Immunocore Holdings reported revenue of $400.02M for fiscal 2025, up 28.95% from fiscal 2024.
Does Immunocore Holdings pay a dividend?
Yes. Immunocore Holdings declared $0.00 per share in dividends for fiscal 2025.
Sources and methodology
Fundamentals come from Immunocore Holdings plc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures